Literature DB >> 16177107

CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef.

Anita Milicic1, David A Price, Peter Zimbwa, Bruce L Booth, Helen L Brown, Philippa J Easterbrook, Kara Olsen, Nicola Robinson, Uzi Gileadi, Andrew K Sewell, Vincenzo Cerundolo, Rodney E Phillips.   

Abstract

CTL play a critical role in the control of HIV and SIV. However, intrinsic genetic instability enables these immunodeficiency viruses to evade detection by CTL through mutation of targeted antigenic sites. These mutations can impair binding of viral epitopes to the presenting MHC class I molecule or disrupt TCR-mediated recognition. In certain regions of the virus, functional constraints are likely to limit the capacity for variation within epitopes. Mutations elsewhere in the protein, however, might still enable immune escape through effects on Ag processing. In this study, we describe the coincident emergence of three mutations in a highly conserved region of Nef during primary HIV-1 infection. These mutations (R69K, A81G, and H87R) flank the HLA B*35-restricted VY8 epitope and persisted to fixation as the early CTL response to this Ag waned. The variant form of Nef showed a reduced capacity to activate VY8-specific CTL, although protein stability and expression levels were unchanged. This effect was associated with altered processing by the proteasome that caused partial destruction of the VY8 epitope. Our data demonstrate that a variant HIV genotype can significantly impair proteasomal epitope processing and substantiate the concept of immune evasion through diminished Ag generation. These observations also indicate that the scale of viral escape may be significantly underestimated if only intraepitope variation is evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177107     DOI: 10.4049/jimmunol.175.7.4618

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Cell type-specific proteasomal processing of HIV-1 Gag-p24 results in an altered epitope repertoire.

Authors:  Nicholas J Steers; Jeffrey R Currier; Gustavo H Kijak; Robert C di Targiani; Ashima Saxena; Mary A Marovich; Jerome H Kim; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

2.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

3.  The immune response to the RT181-189 epitope in HIV-1-infected patients is associated with viral sequence polymorphism flanking the epitope.

Authors:  Yovana Pacheco; Clotilde Allavena; Yannick Guilloux; Sandra M Mueller-Schmucker; Angela G Hueckelhoven; Elisabeth André-Garnier; François Cleon; Virginie Ferré; Audrey Rodallec; Eric Billaud; Thomas Harrer; François Raffi; Dorian McIlroy
Journal:  J Clin Immunol       Date:  2011-04-14       Impact factor: 8.317

4.  Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.

Authors:  Sandra M Mueller; Birgit Schaetz; Kathrin Eismann; Silke Bergmann; Michael Bauerle; Matthias Schmitt-Haendle; Hauke Walter; Barbara Schmidt; Klaus Korn; Heinrich Sticht; Bernd Spriewald; Ellen G Harrer; Thomas Harrer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

5.  Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.

Authors:  Stefan Tenzer; Edmund Wee; Anne Burgevin; Guillaume Stewart-Jones; Lone Friis; Kasper Lamberth; Chih-hao Chang; Mikkel Harndahl; Mirjana Weimershaus; Jan Gerstoft; Nadja Akkad; Paul Klenerman; Lars Fugger; E Yvonne Jones; Andrew J McMichael; Søren Buus; Hansjörg Schild; Peter van Endert; Astrid K N Iversen
Journal:  Nat Immunol       Date:  2009-05-03       Impact factor: 25.606

6.  Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response.

Authors:  Christof Geldmacher; Ian S Metzler; Sodsai Tovanabutra; Tedi E Asher; Emma Gostick; David R Ambrozak; Constantinos Petrovas; Alexandra Schuetz; Njabulo Ngwenyama; Gustavo Kijak; Leonard Maboko; Michael Hoelscher; Francine McCutchan; David A Price; Daniel C Douek; Richard A Koup
Journal:  Blood       Date:  2009-06-19       Impact factor: 22.113

7.  T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope.

Authors:  Angela Wahl; William McCoy; Fredda Schafer; Wilfried Bardet; Rico Buchli; Daved H Fremont; William H Hildebrand
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

8.  Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes.

Authors:  Keri L Schaubert; David A Price; Janelle R Salkowitz; Andrew K Sewell; John Sidney; Tedi E Asher; Sylvie E Blondelle; Sharon Adams; Francesco M Marincola; Aviva Joseph; Alessandro Sette; Daniel C Douek; Velpandi Ayyavoo; Walter Storkus; Ming-Ying Leung; Hwee L Ng; Otto O Yang; Harris Goldstein; Darcy B Wilson; June Kan-Mitchell
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

9.  Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.

Authors:  Bin Li; Adrianne D Gladden; Marcus Altfeld; John M Kaldor; David A Cooper; Anthony D Kelleher; Todd M Allen
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

10.  Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Authors:  Szu-Han Huang; Yanqin Ren; Allison S Thomas; Dora Chan; Stefanie Mueller; Adam R Ward; Shabnum Patel; Catherine M Bollard; Conrad Russell Cruz; Sara Karandish; Ronald Truong; Amanda B Macedo; Alberto Bosque; Colin Kovacs; Erika Benko; Alicja Piechocka-Trocha; Hing Wong; Emily Jeng; Douglas F Nixon; Ya-Chi Ho; Robert F Siliciano; Bruce D Walker; R Brad Jones
Journal:  J Clin Invest       Date:  2018-01-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.